{"name":"Effect of sofosbuvir-based treatment on clinical outcomes of patients with COVID-19: a systematic review and meta-analysis of randomised controlled trials","id":"19","link":"https://www.sciencedirect.com/science/article/pii/S0924857922000334?casa_token=_K8mELvPQDcAAAAA:cO15nzb0nhIMG54SOi0vm6ZrT8NxffKVwU8w7troRAXDfQTi6Ea6tgtXcGF88P_eTTk3_wUnLaE","dbsearches":"4","refs":"https://docs.google.com/spreadsheets/d/1br-fCN4BKWOpho3RCJjUy7JgFPQVUhZIAYEx2ovMnec/edit#gid=0","references":[{"doi":"10.1093/jac/dkaa332","date":"2020-07-03","title":"Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial","abstract":"Background\nNew therapeutic options are urgently needed to tackle the novel coronavirus disease 2019 (COVID-19).\n\n Repurposing existing pharmaceuticals provides an immediate treatment opportunity.\n\n We assessed the efficacy of sofosbuvir and daclatasvir with ribavirin for treating patients with COVID-19.\nMethods\nThis was a single-centre, randomized controlled trial in adults with moderate COVID-19 admitted to the Ghaem Shahr Razi Hospital in Mazandaran Province, Iran.\n\n Patients were randomly assigned to 400?mg sofosbuvir, 60?mg daclatasvir and 1200?mg ribavirin (intervention group) or to standard care (control group).\n\n The primary endpoint of this study was length of hospital stay.\n\n This study is registered by IRCT.\n\nir under the ID: IRCT20200328046886N1.\nResults\nBetween 20 March 2020 and 8 April 2020, 48 patients were recruited; 24 patients were randomly assigned to the intervention group and 24 to the control group.\n\n The median duration of hospital stay was 6?days in both groups (P?=?0.398).\n\n The number of ICU admissions in the sofosbuvir/daclatasvir/ribavirin group was not significantly lower than the control group (0 versus 4, P?=?0.109).\n\n There was no difference in the number of deaths between the groups (0 versus 3, P?=?0.234).\n\n The cumulative incidence of recovery was higher in the sofosbuvir/daclatasvir/ribavirin arm (Gray’s P?=?0.033).\n\n\nConclusions\nThis randomized trial was too small to make definitive conclusions.\n\n There were trends in favour of the sofosbuvir/daclatasvir/ribavirin arm for recovery and lower death rates.\n\n However, there was an imbalance in the baseline characteristics between the arms.\n\n Larger randomized trials should be conducted to investigate this treatment further.\n\n\n","id":"PMC7454669","idformat":"PMC","foundapis":"_PMC_CROSSREF","miscinfo":"","authors":[{"firstname":"Hamideh","surname":"Abbaspour Kasgari","email":"NULL","contributions":"1"},{"firstname":"Siavash","surname":"Moradi","email":"NULL","contributions":"1"},{"firstname":"Amir Mohammad","surname":"Shabani","email":"NULL","contributions":"1"},{"firstname":"Farhang","surname":"Babamahmoodi","email":"NULL","contributions":"2"},{"firstname":"Farhang","surname":"Babamahmoodi","email":"NULL","contributions":"0"},{"firstname":"Ali Reza","surname":"Davoudi Badabi","email":"NULL","contributions":"1"},{"firstname":"Lotfollah","surname":"Davoudi","email":"NULL","contributions":"1"},{"firstname":"Ahmad","surname":"Alikhani","email":"NULL","contributions":"1"},{"firstname":"Akbar","surname":"Hedayatizadeh Omran","email":"NULL","contributions":"1"},{"firstname":"Majid","surname":"Saeedi","email":"NULL","contributions":"2"},{"firstname":"Shahin","surname":"Merat","email":"NULL","contributions":"3"},{"firstname":"Hannah","surname":"Wentzel","email":"NULL","contributions":"6"},{"firstname":"Hannah","surname":"Wentzel","email":"NULL","contributions":"0"},{"firstname":"Anna","surname":"Garratt","email":"NULL","contributions":"2"},{"firstname":"Jacob","surname":"Levi","email":"NULL","contributions":"3"},{"firstname":"Bryony","surname":"Simmons","email":"NULL","contributions":"3"},{"firstname":"Andrew","surname":"Hill","email":"NULL","contributions":"4"},{"firstname":"                          Hafez","surname":"Tirgar Fakheri","email":"hafezfakheri@gmail.com","contributions":"1"}]},{"doi":"10.1080/14787210.2021.1950532","date":"2023-04-29","title":"'RETRACTED ARTICLE: Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: a multicenter Egyptian study'","abstract":"Unknown Abstract","id":"10.1080/14787210.2021.1950532","idformat":"CROSSREF","foundapis":"","miscinfo":"PUBLISHER: Informa UK Limited","authors":[{"firstname":"Mahmoud","surname":"El-Bendary","email":"xref no email","contributions":"1"},{"firstname":" Sherief","surname":"Abd-Elsalam","email":"xref no email","contributions":"1"},{"firstname":" Tamer","surname":"Elbaz","email":"xref no email","contributions":"1"},{"firstname":" Wafaa","surname":"El-Akel","email":"xref no email","contributions":"1"},{"firstname":" Ahmed","surname":"Cordie","email":"xref no email","contributions":"1"},{"firstname":" Tamer","surname":"Elhadidy","email":"xref no email","contributions":"1"},{"firstname":" Hatem","surname":"Elalfy","email":"xref no email","contributions":"1"},{"firstname":" Khaled","surname":"Farid","email":"xref no email","contributions":"1"},{"firstname":" Mohamed","surname":"Elegezy","email":"xref no email","contributions":"1"},{"firstname":" Adel","surname":"El-Badrawy","email":"xref no email","contributions":"1"},{"firstname":" Mustafa","surname":"Neamatallah","email":"xref no email","contributions":"1"},{"firstname":" Mohamed","surname":"Abd Elghafar","email":"xref no email","contributions":"1"},{"firstname":" Marwa","surname":"Salama","email":"xref no email","contributions":"1"},{"firstname":" Mohamed","surname":"AbdAllah","email":"xref no email","contributions":"1"},{"firstname":" Mahmoud","surname":"Essam","email":"xref no email","contributions":"1"},{"firstname":" Mostafa","surname":"El-Shazly","email":"xref no email","contributions":"1"},{"firstname":"       Gamal","surname":"Esmat","email":"xref no email","contributions":"1"}]},{"doi":"10.1093/jac/dkaa331","date":"2020-07-03","title":"The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19","abstract":"Objectives\nSofosbuvir and daclatasvir are direct-acting antivirals highly effective against hepatitis C virus.\n\n There is some in silico and in vitro evidence that suggests these agents may also be effective against SARS-CoV-2. This trial evaluated the effectiveness of sofosbuvir in combination with daclatasvir in treating patients with COVID-19.\nMethods\nPatients with a positive nasopharyngeal swab for SARS-CoV-2 on RT–PCR or bilateral multi-lobar ground-glass opacity on their chest CT and signs of severe COVID-19 were included.\n\n Subjects were divided into two arms with one arm receiving ribavirin and the other receiving sofosbuvir/daclatasvir.\n\n All participants also received the recommended national standard treatment which, at that time, was lopinavir/ritonavir and single-dose hydroxychloroquine.\n\n The primary endpoint was time from starting the medication until discharge from hospital with secondary endpoints of duration of ICU stay and mortality.\n\n\nResults\nSixty-two subjects met the inclusion criteria, with 35 enrolled in the sofosbuvir/daclatasvir arm and 27 in the ribavirin arm.\n\n The median duration of stay was 5?days for the sofosbuvir/daclatasvir group and 9?days for the ribavirin group.\n\n The mortality in the sofosbuvir/daclatasvir group was 2/35 (6%) and 9/27 (33%) for the ribavirin group.\n\n The relative risk of death for patients treated with sofosbuvir/daclatasvir was 0.17 (95% CI 0.04–0.73, P?=?0.02) and the number needed to treat for benefit was 3.6 (95% CI 2.1–12.1, P?&lt;?0.01).\n\n\nConclusions\nGiven these encouraging initial results, and the current lack of treatments proven to decrease mortality in COVID-19, further investigation in larger-scale trials seems warranted.\n\n\n","id":"PMC7529105","idformat":"PMC","foundapis":"_PMC_CROSSREF","miscinfo":"","authors":[{"firstname":"Gholamali","surname":"Eslami","email":"NULL","contributions":"1"},{"firstname":"Sajedeh","surname":"Mousaviasl","email":"NULL","contributions":"1"},{"firstname":"Esmat","surname":"Radmanesh","email":"NULL","contributions":"1"},{"firstname":"Saeed","surname":"Jelvay","email":"NULL","contributions":"1"},{"firstname":"Saeid","surname":"Bitaraf","email":"NULL","contributions":"1"},{"firstname":"Bryony","surname":"Simmons","email":"NULL","contributions":"0"},{"firstname":"Hannah","surname":"Wentzel","email":"NULL","contributions":"0"},{"firstname":"Andrew","surname":"Hill","email":"NULL","contributions":"0"},{"firstname":"Anahita","surname":"Sadeghi","email":"NULL","contributions":"1"},{"firstname":"James","surname":"Freeman","email":"NULL","contributions":"1"},{"firstname":"Shokrollah","surname":"Salmanzadeh","email":"NULL","contributions":"1"},{"firstname":"Hani","surname":"Esmaeilian","email":"NULL","contributions":"1"},{"firstname":"Morteza","surname":"Mobarak","email":"NULL","contributions":"1"},{"firstname":"Ramin","surname":"Tabibi","email":"NULL","contributions":"1"},{"firstname":"Amir Hosein","surname":"Jafari Kashi","email":"NULL","contributions":"1"},{"firstname":"Zahra","surname":"Lotfi","email":"NULL","contributions":"1"},{"firstname":"Seyed Mehdi","surname":"Talebzadeh","email":"NULL","contributions":"1"},{"firstname":"Aseni","surname":"Wickramatillake","email":"NULL","contributions":"1"},{"firstname":"Mahboobeh","surname":"Momtazan","email":"NULL","contributions":"1"},{"firstname":"Majid","surname":"Hajizadeh Farsani","email":"NULL","contributions":"1"},{"firstname":"Sedigheh","surname":"Marjani","email":"NULL","contributions":"1"},{"firstname":"                          Sara","surname":"Mobarak","email":"s.mobarak@abadanums.ac.ir","contributions":"1"}]},{"doi":"10.1093/jac/dkaa501","date":"2020-11-09","title":"Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial","abstract":"Introduction\nEffective treatments are urgently needed to tackle the novel coronavirus disease 2019 (COVID-19).\n\n This trial aims to evaluate sofosbuvir and daclatasvir versus standard care for outpatients with mild COVID-19 infection.\n\n\nMethods\nThis was a randomized controlled clinical trial in outpatients with mild COVID-19. Patients were randomized into a treatment arm receiving sofosbuvir/daclatasvir plus hydroxychloroquine or a control arm receiving hydroxychloroquine alone.\n\n The primary endpoint of the trial was symptom alleviation after 7?days of follow-up.\n\n The secondary endpoint of the trial was hospital admission.\n\n Fatigue, dyspnoea and loss of appetite were investigated after 1?month of follow-up.\n\n This study is registered with the IRCT.\n\nir under registration number IRCT20200403046926N1.\nResults\nBetween 8 April 2020 and 19 May 2020, 55 patients were recruited and allocated to either the sofosbuvir/daclatasvir treatment arm (n?=?27) or the control arm (n?=?28).\n\n Baseline characteristics were similar across treatment arms.\n\n There was no significant difference in symptoms at Day 7. One patient was admitted to hospital in the sofosbuvir/daclatasvir arm and four in the control arm, but the difference was not significant.\n\n After 1?month of follow-up, two patients reported fatigue in the sofosbuvir/daclatasvir arm and 16 in the control arm; P?&lt;?0.001.\nConclusions\nIn this study, sofosbuvir/daclatasvir did not significantly alleviate symptoms after 7?days of treatment compared with control.\n\n Although fewer hospitalizations were observed in the sofosbuvir/daclatasvir arm, this was not statistically significant.\n\n Sofosbuvir/daclatasvir significantly reduced the number of patients with fatigue and dyspnoea after 1?month.\n\n Larger, well-designed trials are warranted.\n\n\n","id":"PMC7798988","idformat":"PMC","foundapis":"_PMC_CROSSREF","miscinfo":"","authors":[{"firstname":"Fatemeh","surname":"Roozbeh","email":"NULL","contributions":"1"},{"firstname":"Majid","surname":"Saeedi","email":"NULL","contributions":"0"},{"firstname":"Reza","surname":"Alizadeh-Navaei","email":"NULL","contributions":"1"},{"firstname":"Akbar","surname":"Hedayatizadeh-Omran","email":"NULL","contributions":"1"},{"firstname":"Shahin","surname":"Merat","email":"NULL","contributions":"0"},{"firstname":"Hannah","surname":"Wentzel","email":"NULL","contributions":"0"},{"firstname":"Hannah","surname":"Wentzel","email":"NULL","contributions":"0"},{"firstname":"Jacob","surname":"Levi","email":"NULL","contributions":"0"},{"firstname":"Andrew","surname":"Hill","email":"NULL","contributions":"0"},{"firstname":"                          Amir","surname":"Shamshirian","email":"shamshirian.amir@gmail.com","contributions":"1"}]},{"doi":"10.23750/abm.v91i4.10877","date":"2020-11-03","title":"Efficacy and safety of sofosbuvir/ledipasvir in treatment of patients with COVID-19; A randomized clinical trial","abstract":"Background:\nThere is no study regarding the use of SOF/LDP in treatment of COVID-19.\nObjectives:\nIn this study, the efficacy and safety of SOF/LDP were assessed in treatment of patients with mild to moderate COVID-19.\nMethods:\nAmong an open-label randomized clinical trial, 82 patients with mild to moderated COVID-19 were assigned to receive either SOF/LDP 400/100 mg daily plus the standard of care (SOF/LDP group, n=42) or the standard of care alone (control group, n=40) for 10 days.\n\n Time to clinical response, rate of clinical response, duration of hospital and ICU stay and 14-day mortality were assessed.\n\n\nResults:\nClinical response occurred in 91.46% of patients.\n\n Although rates of clinical response were comparable between the groups but it occurred faster in the SOF/LDP group than the control group (2 vs.\n\n 4 days respectively, P= 0.02).\n\n Supportive cares were provided in the medical wards for most patients but 17.07% of patients were transferred to ICU during the hospitalization course.\n\n However, durations of hospital and ICU stay were comparable between the groups.\n\n 14-day mortality rate was 7.14% and 7.5% in the SOF/ LDP and control groups respectively.\n\n No adverse effects leading to drug discontinuation occurred.\n\n Gastrointestinal events (nausea, vomiting and diarrhea) were the most common side effects (15.85%).\n\n\nConclusion:\nAdded to the standard of care, SOF/LDP accelerated time to the clinical response.\n\n However, rate of clinical response, duration of hospital and ICU stay and 14-day mortality were not different.\n\n No significant adverse event was detected.\n\n More randomized clinical trials with larger sample sizes are needed to confirm the efficacy and safety of SOF/LDP in the treatment of COVID-19. (www.\n\nactabiomedica.\n\nit)\n","id":"PMC7927527","idformat":"PMC","foundapis":"_PMC","miscinfo":"","authors":[{"firstname":"Anahid","surname":"Nourian","email":"NULL","contributions":"1"},{"firstname":"Hossein","surname":"Khalili","email":"NULL","contributions":"1"},{"firstname":"Zahra","surname":"Ahmadinejad","email":"NULL","contributions":"1"},{"firstname":"Hamid","surname":"Emadi Kouchak","email":"NULL","contributions":"1"},{"firstname":"Sirous","surname":"Jafari","email":"NULL","contributions":"1"},{"firstname":"Sayed Ali","surname":"Dehghan Manshadi","email":"NULL","contributions":"1"},{"firstname":"Mehrnaz","surname":"Rasolinejad","email":"NULL","contributions":"1"},{"firstname":"                          Abbas","surname":"Kebriaeezadeh","email":"NULL","contributions":"1"}]},{"doi":"10.1093/jac/dkab152","date":"2021-04-13","title":"Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial","abstract":"Objectives\nSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19 pandemic.\n\n The majority of patients experience asymptomatic to mild self-limited disease, but some cases progress to respiratory and multi-organ failure.\n\n However, so far, no approved antiviral therapy has been available for treatment of COVID-19. Sofosbuvir/velpatasvir (SOF/VEL) is an approved anti-HCV drug that is capable of suppressing other families of positive-sense RNA viruses with conserved polymerase and may be effective against SARS-CoV-2. This study was conducted to evaluate the efficacy of the SOF/VEL combination in addition to the national standard of care versus the national standard of care alone (hydroxychloroquine and lopinavir/ritonavir as well as supportive care) in patients with moderate to severe COVID-19 infection.\n\n\nMethods\nThis single-centre, randomized, open-labelled, prospective clinical trial was done in patients with moderate to severe COVID-19 admitted to Farabi Hospital in Kermanshah Province, Iran.\n\n Eligible patients were randomly assigned in a 1:1 ratio to the SOF/VEL arm (SOF/VEL plus the national standard of care) or the control arm (the national standard of care alone).\n\n The main outcome of the study was the mortality on Day 28 after randomization.\n\n Secondary outcomes were time from the start of medication to clinical improvement, hospital length of stay, need for mechanical ventilation, duration of mechanical ventilation and conversion of RT–PCR results from positive to negative from the time of randomization to discharge.\n\n Adverse events were evaluated in all patients who started their assigned treatment.\n\n\nResults\nBetween 11 April and 8 June 2020, 80 patients were recruited and randomly assigned into the SOF/VEL (n?=?40) and control (n?=?40) arms.\n\n The primary outcome was not significantly different between the two arms (P?=?1.00).\n\n Secondary outcomes, including time to clinical improvement, hospital length of stay, need for mechanical ventilation, duration of mechanical ventilation and RT–PCR conversion, were not significantly different between arms either (P?&gt;?0.05).\n\n SOF/VEL treatment and the national standard of care were tolerated similarly.\n\n\nConclusions\nAlthough treatment with SOF/VEL was safe, adding SOF/VEL to the standard of care did not improve the clinical status or reduce mortality in patients with moderate to severe COVID-19. However, larger randomized clinical trials including more parameters are needed for accurate estimation of the efficacy of SOF/VEL.\n\n\n","id":"PMC8194643","idformat":"PMC","foundapis":"_PMC_CROSSREF","miscinfo":"","authors":[{"firstname":"Babak","surname":"Sayad","email":"NULL","contributions":"1"},{"firstname":"Reza","surname":"Khodarahmi","email":"rkhodarahmi@mbrc.ac.ir","contributions":"2"},{"firstname":"Reza","surname":"Khodarahmi","email":"rkhodarahmi@mbrc.ac.ir","contributions":"0"},{"firstname":"Farid","surname":"Najafi","email":"NULL","contributions":"1"},{"firstname":"Ronak","surname":"Miladi","email":"NULL","contributions":"1"},{"firstname":"Zeinab","surname":"Mohseni Afshar","email":"NULL","contributions":"1"},{"firstname":"Feizollah","surname":"Mansouri","email":"NULL","contributions":"1"},{"firstname":"Zohreh","surname":"Rahimi","email":"NULL","contributions":"1"},{"firstname":"Maria","surname":"Shirvani","email":"NULL","contributions":"1"},{"firstname":"Mehdi","surname":"Salimi","email":"NULL","contributions":"1"},{"firstname":"Siavash","surname":"Vaziri","email":"NULL","contributions":"1"},{"firstname":"Alireza","surname":"Janbakhsh","email":"NULL","contributions":"1"},{"firstname":"Fatemeh","surname":"Khosravi Shadmani","email":"NULL","contributions":"1"},{"firstname":"Arezoo","surname":"Bozorgomid","email":"NULL","contributions":"1"},{"firstname":"Mohammad Hossein","surname":"Zamanian","email":"NULL","contributions":"1"},{"firstname":"                          Mandana","surname":"Afsharian","email":"NULL","contributions":"1"}]},{"doi":"10.1093/jac/dkaa334","date":"2020-07-03","title":"Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial","abstract":"Background\nCurrently no effective antiviral therapy has been found to treat COVID-19. The aim of this trial was to assess if the addition of sofosbuvir and daclatasvir improved clinical outcomes in patients with moderate or severe COVID-19.\nMethods\nThis was an open-label, multicentre, randomized controlled clinical trial in adults with moderate or severe COVID-19 admitted to four university hospitals in Iran.\n\n Patients were randomized into a treatment arm receiving sofosbuvir and daclatasvir plus standard care, or a control arm receiving standard care alone.\n\n The primary endpoint was clinical recovery within 14?days of treatment.\n\n The study is registered with IRCT.\n\nir under registration number IRCT20200128046294N2.\nResults\nBetween 26 March and 26 April 2020, 66 patients were recruited and allocated to either the treatment arm (n?=?33) or the control arm (n?=?33).\n\n Clinical recovery within 14?days was achieved by 29/33 (88%) in the treatment arm and 22/33 (67%) in the control arm (P?=?0.076).\n\n The treatment arm had a significantly shorter median duration of hospitalization [6?days (IQR 4–8)] than the control group [8?days (IQR 5–13)]; P?=?0.029. Cumulative incidence of hospital discharge was significantly higher in the treatment arm versus the control (Gray’s P?=?0.041).\n\n Three patients died in the treatment arm and five in the control arm.\n\n No serious adverse events were reported.\n\n\nConclusions\nThe addition of sofosbuvir and daclatasvir to standard care significantly reduced the duration of hospital stay compared with standard care alone.\n\n Although fewer deaths were observed in the treatment arm, this was not statistically significant.\n\n Conducting larger scale trials seems prudent.\n\n\n","id":"PMC7454592","idformat":"PMC","foundapis":"_PMC_CROSSREF","miscinfo":"","authors":[{"firstname":"Anahita","surname":"Sadeghi","email":"NULL","contributions":"1"},{"firstname":"Ali","surname":"Ali Asgari","email":"NULL","contributions":"2"},{"firstname":"Ali","surname":"Ali Asgari","email":"NULL","contributions":"0"},{"firstname":"Alireza","surname":"Norouzi","email":"NULL","contributions":"1"},{"firstname":"Zahedin","surname":"Kheiri","email":"NULL","contributions":"1"},{"firstname":"Amir","surname":"Anushirvani","email":"NULL","contributions":"1"},{"firstname":"Mahnaz","surname":"Montazeri","email":"NULL","contributions":"1"},{"firstname":"Hadiseh","surname":"Hosamirudsai","email":"NULL","contributions":"1"},{"firstname":"Shirin","surname":"Afhami","email":"NULL","contributions":"1"},{"firstname":"Elham","surname":"Akbarpour","email":"NULL","contributions":"1"},{"firstname":"Rasoul","surname":"Aliannejad","email":"NULL","contributions":"2"},{"firstname":"Rasoul","surname":"Aliannejad","email":"NULL","contributions":"0"},{"firstname":"Amir Reza","surname":"Radmard","email":"NULL","contributions":"1"},{"firstname":"Amir H","surname":"Davarpanah","email":"NULL","contributions":"1"},{"firstname":"Jacob","surname":"Levi","email":"NULL","contributions":"0"},{"firstname":"Hannah","surname":"Wentzel","email":"NULL","contributions":"0"},{"firstname":"Ambar","surname":"Qavi","email":"NULL","contributions":"1"},{"firstname":"Anna","surname":"Garratt","email":"NULL","contributions":"0"},{"firstname":"Bryony","surname":"Simmons","email":"NULL","contributions":"0"},{"firstname":"Andrew","surname":"Hill","email":"NULL","contributions":"0"},{"firstname":"                          Shahin","surname":"Merat","email":"merat@tums.ac.ir","contributions":"0"}]},{"doi":"10.1002/jmv.27264","date":"2021-08-08","title":"Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID?19: A randomized controlled trial","abstract":"Only a few treatments are approved for coronavirus disease?2019 (COVID?19) infections, with continuous debate about their clinical impact.\n\n Repurposing antiviral treatments might prove the fastest way to identify effective therapy.\n\n This trial aimed to evaluate the efficacy and safety of sofosbuvir (SOF) plus daclatasvir (DCV) or ravidasvir (RDV) added to standard care (SOC) for patients with moderate and severe COVID?19 infection.\n\n Multicentre parallel randomized controlled open?label trial.\n\n One hundred and twenty eligible patients with moderate and severe COVID?19 infection were randomized to one of the study arms.\n\n Ten days of treatment with SOF plus DCV or RDV in addition to the standard of care compared to SOC.\n\n Follow up in 7 days.\n\n Sum of the counted symptoms at 7 and 10 days, mean change in oxygen saturation level, viral negativity, and rate of intensive care unit (ICU) admission.\n\n Compared to SOC, the SOF?DCV group experienced a significantly lower sum of the counted symptoms (fever, headache, generalized aches, or respiratory distress) combined with no evidence of deterioration (ICU admission and mechanical ventilation) on Days 7 and 10 of treatment.\n\n Oxygen saturation also significantly improved among the SOF?DCV group compared to SOC starting from Day 4. The study also showed positive trends regarding the efficacy of SOF?DCV with a lower incidence of mortality.\n\n On the other hand, adding SOF?RDV to SOC did not show significant improvements in endpoints.\n\n The results support the efficacy and safety of SOF?DCV as an add?on to SOC for the treatment of moderate to severe COVID?19 infections.\n\n","id":"PMC8426808","idformat":"PMC","foundapis":"_PMC_CROSSREF","miscinfo":"","authors":[{"firstname":"Sherif","surname":"Abbass","email":"sherif533@hotmail.com","contributions":"1"},{"firstname":"Ehab","surname":"Kamal","email":"NULL","contributions":"2"},{"firstname":"Ehab","surname":"Kamal","email":"NULL","contributions":"0"},{"firstname":"Mohsen","surname":"Salama","email":"NULL","contributions":"2"},{"firstname":"Mohsen","surname":"Salama","email":"NULL","contributions":"0"},{"firstname":"Tary","surname":"Salman","email":"NULL","contributions":"1"},{"firstname":"Alyaa","surname":"Sabry","email":"NULL","contributions":"1"},{"firstname":"Wael","surname":"Abdel?Razek","email":"NULL","contributions":"1"},{"firstname":"Sherine","surname":"Helmy","email":"NULL","contributions":"1"},{"firstname":"Ahmed","surname":"Abdelgwad","email":"NULL","contributions":"1"},{"firstname":"Neamt","surname":"Sakr","email":"NULL","contributions":"1"},{"firstname":"Mohamed","surname":"Elgazzar","email":"NULL","contributions":"1"},{"firstname":"Mohamed","surname":"Einar","email":"NULL","contributions":"1"},{"firstname":"Mahmoud","surname":"Farouk","email":"NULL","contributions":"1"},{"firstname":"Mounir","surname":"Saif","email":"NULL","contributions":"1"},{"firstname":"Ismail","surname":"Shehab","email":"NULL","contributions":"1"},{"firstname":"Eman","surname":"El?hosieny","email":"NULL","contributions":"1"},{"firstname":"Mai","surname":"Mansour","email":"NULL","contributions":"1"},{"firstname":"Doaa","surname":"Mahdi","email":"NULL","contributions":"1"},{"firstname":"El?Sayed","surname":"Tharwa","email":"NULL","contributions":"1"},{"firstname":"Mostafa","surname":"Salah","email":"NULL","contributions":"1"},{"firstname":"Ola","surname":"Elrouby","email":"NULL","contributions":"1"},{"firstname":"                          Imam","surname":"Waked","email":"NULL","contributions":"1"}]}]}